Mavoglurant (AFQ056), a candidate for the treatment of fragile X syndrome (FXS), restored functionality in sensory networks but…
Catarina Silva, MSc
With over three years of experience in the medical communications business, Catarina holds a BSc. in Biomedical Sciences and a MSc. in Neurosciences. Apart from writing, she has been involved in patient-oriented translational and clinical research.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Catarina Silva, MSc
Given the genetic variability behind the disease, current clinical diagnostic criteria for fragile X-linked tremor/ataxia syndrome do not accurately…
An older existing medication that targets a pathway thought to be involved in fragile X syndrome failed to reverse…